Materialandmethods
Studypopulation
Allindividualsaged
o65yrswereinvitedbyapersonal
lettertoreceive,atreducedcost,inßuenzaandpneumococcal
vaccinesduringan8-weekperiodfromtheendofSeptember
tothemiddleofNovemberforeachoftheyears1998Ð2000.

Thevaccinationcampaignwasalsoadvertisedinthedaily

papersandonpostersatgeneralpractitioners
9ofÞcesandat
pharmacies.In1998,thetotalstudypopulationwas259,627,and
ofthese77,177receivedbothvaccines,23,224receivedonly

theinßuenzavaccineand841onlythepneumococcalvaccine

[22,23].In1999(themaincohortforthecurrentanalysis),
thestudypopulationwaslargelythesameasin1998.
However,the1999cohortalsoincludedpersonswhothat

yearbecame65yrsofage,butexcludedthosewhohaddied

during1998.Theresultingnumberofpersonsof
o65yrsof
agewastherefore258,747,ofwhich134,045didnotaccept
theofferofvaccination.Ofthoseinthevaccinatedgroup,

72,107receivedbothvaccines,29,346receivedonlythe

inßuenzavaccineand292onlythepneumococcalvaccine.
Inaddition,22,957individualswhohadreceivedthepneu-
mococcalvaccinationin1998,andwhodidnotacceptthe

offerofinßuenzavaccinationin1999,wereincludedinthe

analysis.Thevaccinesusedwerethe23-valentpneumococcalpoly-
saccharidevaccine(PneumovaxfromPasteur-MerieuxMSD,
Pennsylvania,PA,USA;Pnu-ImunefromWyeth-Lederle,

NewYork,NY,USA;orPneumokockvaccinfromSBL

Vaccin,Stockholm,Sweden)andatrivalentsplit-virion
inßuenzavaccine(Begrivac;ChironBehringGmbH&Co.,
Marburg,Germany,1999/2000)containing15
mgofA/
Beijing/262/95(H1N1),A/Sydney/5/97(H3N2)andB/Harbin/

7/94(B/Beijing/184/93-likestrain).
Generalpractitionersperformedmostofthevaccinations.
Atvaccination,thephysiciannotedeachindividual
9sname
andpersonalidentiÞcationcode(uniqueforeachSwedish

citizen),andwhetheroneorbothvaccinesweregiven.These
datawerethenenteredinadatabaseattheDepartmentof
CommunicableDiseaseControlandPrevention.Forana-

lyses,thevaccinationdatawerematchedwithdischarge

diagnosesaccordingtotheInternationalClassiÞcationof

Diseases,tenthrevision(ICD-10-CM),togetherwithmortal-
itydataforallindividualsaged
o65yrshospitalisedin
StockholmCountyfromDecember1999throughNovember

2000.Aquestionnaireconcerningunderlyinghealthanddemo-
graphicdatawassenttoarandomsampleof10,000
individualsaged
o65yrsinStockholmCountybetween
December2000andJanuary2001withtheaimtocharacterise

possibleconfoundersinthecomparisonofthevaccinatedand
unvaccinatedcohorts.Theresultsofthisstudyhavebeen
publishedelsewhere[24].
End-points
Theprimaryend-pointswereincidenceofhospitaladmis-
sions,numberofdaysinhospital,andin-hospitaldeathsdue
toinßuenza(ICD-10:J10.0,J10.1,J10.8,J11.0andJ11.8),
pneumonia(ICD-10:J12Ð18,J69.0andA48.1)andIPD

(ICD-10:A40.3andG00.1)inthevaccinated
versustheunvaccinatedcohort.Anend-pointdiagnosiswasaccepted
irrespectiveofwhetheritwasontheÞrst,secondorthirdof

thedischargediagnoses.However,onlyoneend-pointdiag-

nosis,theÞrsttoappear,perepisodeofhospitaltreatment
wasincludedintheanalysis.
Thevaccinatedcohortincludedindividualswhoreceived
eitherinßuenzaorpneumococcalvaccineorbothvaccines.

Comparisonswiththeunvaccinatedcohortwereperformed
againstthetotalvaccinatedcohort(receivingoneorboth
vaccines),aswellasagainstthosewhoreceivedinßuenzaor

pneumococcalvaccineonly,andagainstthosewhohad

receivedbothvaccines.Theincidenceofhospitaladmissions
andin-hospitaldeathswerecomparedfortheend-point
diagnosesduringthe12-monthstudyperiod,December1999

throughNovember2000.Inaddition,thecohortswere
comparedduringtheinßuenzaseasonwheninßuenzavirus
wascirculatinginthecommunity,December1999through

May2000,andthenoninßuenzaseason,June2000through

November2000.Duringtheinßuenzaseason,therewasa
medium-sized,inßuenzaA(SydneyH3N2)epidemicin
StockholmCounty.
Statisticalmethods
Thestatisticaldifferencesbetweenvaccinatedandunvacci-
natedindividualswereevaluated,usingtheconÞdence

intervalforaproportionandtheChi-squaredtestfor

categoricalvariables.Thereductioninmortalityinvaccinated
peoplewascalculatedfromtheresultsofthelogistic
regressionanalysis.Theadjustedoddsratio(OR)wasused

asanestimateoftherelativerisk.Thus,thereductionin
mortalitywascalculatedas(1-OR)
6100%.Results
Intotal,124,702individuals(48%ofthetargetpopulation)
werevaccinatedwithoneorbothvaccines.Ofthese,101,745

individuals(39%)werevaccinatedduringthe8-weekvaccina-
tioncampaignin1999and22,957hadreceivedpneumococcal
vaccinationduringthevaccinationcampaignin1998,butno

inßuenzavaccinationin1999.Bothvaccinesweregivento
72,107individuals,theinßuenzavaccinealoneto29,346,
andthepneumococcalvaccinealoneto23,249persons.Of

thevaccinatedindividuals,59%werefemales,adistribution

similartothatofallpersonsintheseagegroupsinStockholm
County(60%females).Table1showsthedistributionofthe
Table1.ÐProportionsofvaccinatedindividualsandvaccinesgivenindifferentagegroups
AgeyrsIndividualsnVaccinatedindividuals
#%Vaccinegiven
Inßuenza}%Pneumococcal
z%Both
¤%65Ð741244284610828
75Ð84991185212930
o853520146131023
Total2587474811928
#:totalnumberofvaccinatedindividualswas124,702;
}:n=29,346;z:n=23,249;¤:n=72,107.364B.CHRISTENSONETAL.
 studypopulationbyagegroup,theproportionofvaccinated
personsandthevaccinegiven.
Comparisonoftheratesofhospitalisationindifferentage
groupsbetweenallvaccinatedindividuals(124,702)andthose
unvaccinated(134,045)showedthattheincidenceofhospital
admissionsforalldiagnoseswasloweramongvaccinated

individualsinmost,butnotall,agegroups(table2).For

inßuenza,noeffectwasseenintheyoungestagegroup

(65Ð74yrsofage),whileasigniÞcanteffectforprevention

againstIPDwasseenonlyinthatagegroup.
Comparedwiththeunvaccinatedgroup,theriskforbeing
admittedtohospitalforinßuenza,withorwithoutpneumo-

nia,wassigniÞcantlylowerforthosewhohadreceivedboth

vaccines,OR0.63(95%conÞdenceinterval(CI)0.50Ð0.81;

table3).Thesametendency,althoughnotquitesigniÞcant,
wasseeninthosewhoreceivedonlytheinßuenzavaccine,or
onlythepneumococcalvaccine.Similarly,therewasa

tendencyforthetwovaccinesgivenseparatelytoreduce

admissionsforpneumonia,comparedwiththeunvaccinated

cohort,whilethetwovaccinesgiventogetherwereclearly

additiveandresultedinasigniÞcantlylowerrisk,OR0.71

(95%CI0.65Ð0.75).TheincidenceofadmissionsduetoIPD

was44Ð73%lowerinthosewhoreceivedoneorbothvaccines,
comparedwithnovaccination,butthenumberofcaseswas
toolowtoobtainastatisticalsigniÞcantdifference(table3).
Anadditiveeffectofthetwovaccineswasalsoseenforin-
hospitalmortalityduetopneumoniawitha35%reduction
(95%CI22Ð46)comparedwiththeunvaccinatedgroup
(table4).Atendencytoanadditiveeffectofthetwovaccines
wasalsoseenforinßuenza-relatedmortality,butthenumber

offatalcaseswaslowresultinginawideCI(OR0.29,95%CI

0.06Ð1.31).Theoverallmortalitywas
y40%lowerinthevacci-
natedcohort(n
=124,702),comparedwiththeunvaccinated
cohort(n
=134,045),forallagegroups(table5).Thenumber
ofdeathsper1,000individualsof
o65yrswas39inthe
vaccinatedversus61intheunvaccinatedcohort(p
v0.0001).Thedurationofhospitaltreatmentforinßuenzaand
pneumoniawassigniÞcantlyshorterinthevaccinated

cohortcomparedwiththeunvaccinatedcohort(datanot
shown).Inthosewhohadreceivedbothvaccines,themean
durationofhospitalstayinvaccinated
versusnonvaccinatedwas5.2
versus7.5days(p
v0.005)forinßuenzaand9.9
versus11.3days(p
v0.0004)forpneumonia.Fewerhospitalisations
andshorterdurationofhospitaltreatmentinthevaccinated

cohortledtoareductionofthetotalnumberofdaysin

hospital;56%forinßuenza,38%forpneumoniaand48%for

IPD.Duringtheinßuenzaseason,December1999throughMay
2000,asigniÞcantreductioninhospitaladmissionswasfound

forinßuenza,pneumoniaandIPDinpersonswhohad
receivedbothvaccinescomparedwiththeunvaccinatedgroup
(table6).Duringthenoninßuenzaseason,Junethrough

November2000,therewasstillasigniÞcantlylowerriskfor

pneumoniainthevaccinatedgroupcomparedwiththe
Table2.ÐHospitaladmissionsforinßuenza(withandwithoutinßuenzapneumonia),pneumonia,andinvasivepneumococcal
disease(IPD)per100,000individualsintotalvaccinated(n
=124,702)andunvaccinated(n
=134,045)cohortsindifferentage
groupsDiagnosisInßuenzaPneumoniaIPD
VaccinatedYesNoYesNoYesNo
Subjects65Ð74yrsn80828651108727
OR(95%CI)0.97(0.66Ð1.46)0.78(0.69Ð0.87)0.26(0.086Ð0.78)

p-valuev0.9v0.0001v0.006Subjects75Ð84yrsn162282205727262746
OR(95%CI)0.57(0.43Ð0.76)0.75(0.69Ð0.82)0.59(0.30Ð1.18)

p-valuev0.0001v0.0001v0.12Subjectsw85yrsn24941844875288616
OR(95%CI)0.60(0.40Ð0.86)0.84(0.76Ð0.93)0.40(0.04Ð4.00)

p-valuev0.007v0.001v0.5Subjectsw65yrsn136201182122831532
OR(95%CI)0.67(0.55Ð0.82)0.79(0.75Ð0.84)0.47(0.27Ð0.82)
p-valuev0.0001v0.0001v0.01OR:oddsratio;CI:conÞdenceinterval.Allp-valuecomparisonsareagainsttheunvaccinatedcohort.
Table3.ÐHospitaladmissionsforinßuenza(withandwithoutinßuenzapneumonia),pneumoniaandinvasivepneumococcal
disease(IPD),per100,000individuals
DiagnosisVaccinegiven
InßuenzaPneumococcalBothNone
Subjectsn293462324972107134045
Inßuenza150142128201
OR(95%CI)0.74(0.54Ð1.03)0.70(0.49Ð1.03)0.63(0.5Ð0.81)

p-valuev0.1v0.1v0.001Pneumonia2140208216072283
OR(95%CI)0.94(0.86Ð1.02)0.91(0.82Ð1.00)0.71(0.65Ð0.75)
p-valuev0.2v0.06v0.0001IPD1491832
OR(95%CI)0.42(0.15Ð1.21)0.27(0.06Ð1.14)0.56(0.30Ð1.05)

p-valuev0.1v0.06v0.06OR:oddsratio;CI:conÞdenceinterval.Datatakenfromsubjectsafterreceivingseparateinßuenzaorpneumococcalvaccines,orboth,compared
withnovaccine,betweenDecember1,1999andNovember30,2000.Allp-valuecomparisonsareagainsttheunvaccinatedcohort.
365INFLUENZAANDPNEUMOCOCCALVACCINES
 unvaccinatedgroup,whiletherewasnodifferenceintherate
ofhospitalisationforinßuenzaorIPD.
Theresultofthepostalinquiryof10,000elderlysubjects,
witharesponserateof78%,inconnectionwiththisstudyhas
beenreportedelsewhere[24].Inbrief,itwasshownthat

subjectswithunderlyingchronicdisordershadhigher

vaccinationrates(p
v0.001)thanthosewithoutunderlying
chronicdiseases.Achroniclungdiseasewasnotedin9.2%
amongpersonsvaccinatedagainstinßuenzaandin9.7%

amongpersonsvaccinatedagainstpneumococcalinfection

comparedwith4.6%and5.6%,respectively,forunvaccinated
persons.Amongthepersonswhowerevaccinatedagainst
inßuenzaandpneumococcalinfection,
w17%hadamyocar-
dialdiseasecomparedwith
v12%amongunvaccinated
persons.Elderlyindividualslivinginnursinghomesor
institutionshadhigherinßuenzavaccinationratesthan
thoselivingintheirownhousehold(72%
versus67%).Discussion
ThepresentstudysupportspreviousÞndingsthatinßuenza
andpneumococcalvaccinationiseffectiveinreducing
hospitalisationanddeathinelderlysubjects[22,23].The
vaccinatedcohort
i.e.thosereceivingoneorbothvaccines,
hadanoveralllowerriskforbeinghospitalisedforthemain

end-pointdiagnoses,inßuenza,pneumoniaorIPD,thanthe

nonvaccinatedcohort.Thiseffectwasconsistentthroughall
agegroupsforpneumonia,butnotforinßuenzaandIPD
(table2).Itisusuallyassumedthattheeffectivenessofboth

thesevaccinesdeclinewithincreasingage[5,12].Thiswas

alsothecaseforIPD,whereasigniÞcantprotectionwasonly

foundinthose65Ð74yrsofage.Forinßuenza,however,the

oppositewasfoundwithprotectiononlyintheagegroups

w74yrsofage.However,itisimportanttopointoutthat
onlytheincidenceofhospitalcareforinßuenzawasstudied,

whichwasverylowintheagegroup65Ð74yrsofage,and

thatnodataontheprotectionagainstinßuenza
perse
inthis
agegroupwasobtained.
Thelargenumberofindividualsreceivingonlyoneofthe
twovaccines,permittedtheauthorstoperformanevaluation

oftheeffectivenessofeachvaccineseparately.Inagreement

withearlierretrospectivestudies[17Ð20,25Ð26],therewasa

reduction,althoughnotquitesigniÞcant,ofhospitalisation

forinßuenzaandpneumoniaafterinßuenzavaccination

(table3).
Table4.ÐIn-hospitalmortalityper100,000individualsafterreceivingseparateinßuenzaorpneumococcalvaccines,orboth,
comparedwithnovaccine,betweenDecember1,1999andNovember30,2000
DiagnosisVaccinegiven
InßuenzaPneumococcalBothNone
Subjectsn293462324972107134045
Inßuenza
#6.84.32.89.7
OR(95%CI)0.70(0.15Ð3.21)0.44(0.06Ð3.53)0.29(0.06Ð1.31)

p-valuev0.64v0.42v0.09Pneumonia299.9318.3223.3342.4
OR(95%CI)0.88(0.69Ð1.11)0.93(0.72Ð1.19)0.65(0.54Ð0.78)

p-valuev0.24v0.56v0.0001OR:oddsratio;CI:conÞdenceinterval.
#:withandwithoutinßuenzapneumonia.Allp-valuecomparisonsareagainsttheunvaccinatedcohort.
Table5.ÐDeathsfromallcausesaccordingtoageandvaccinationstatusbetweenDecember1,1999andNovember30,2000
Ageyrs
65Ð7475Ð84
o85o65Vaccinated#YesNoYesNoYesNoYesNo
Individualsn573776705151280478381604519156124702134045

Deathsper100014.623.541.064.1121.8185.939.261.2

OR(95%CI)0.61(0.56Ð0.67)0.62(0.59Ð0.66)0.61(0.57Ð0.65)0.63(0.60Ð0.65)

p-valuev0.00001v0.00001v0.0001v0.00001OR:oddsratio;CI:conÞdenceinterval.
#:vaccinatedwithoneorbothvaccines.
Table6.ÐHospitaladmissionsper100,000individualsperyearforinßuenza(withandwithoutpneumonia),pneumonia,and
invasivepneumococcaldisease(IPD)
DiagnosisInßuenzaPneumoniaIPD
VaccinatedYesNoYesNoYesNo
Inßuenzaseason247391178427511349
OR(95%CI)0.63(0.53Ð0.75)0.64(0.60Ð0.69)0.28(0.14Ð0.55)

p-valuev0.0001v0.0001v0.001Noninßuenzaseason812143118141915
OR(95%CI)0.47(0.15Ð1.42)0.79(0.73Ð0.85)1.49(0.76Ð2.21)

p-valuev0.16v0.0001v0.23Datatakenfromindividualswhohadreceivedbothvaccines(n
=72,107),comparedwithunvaccinatedpersons(n
=134,045)duringtheinßuenza
season(December1,1999toMay31,2000),andthenoninßuenzaseason(June1,2000toNovember30,2000).OR:oddsratio;CI:conÞdence

interval.Allp-valuecomparisonsareagainsttheunvaccinatedcohort.
366B.CHRISTENSONETAL.
 Theeffectivenessofpneumococcalvaccinationaloneinthe
preventionofpneumonia(9%)almostreachedstatistical
signiÞcance(p
v0.06).Thisprotectivelevelwascomparable
withthosefoundduringnoninßuenzaseasons;12%during

theÞrststudyyear[23]and21%inthepresentstudy(table6),
whennoadditiveeffectfromtheinßuenzavaccinecanbe
expectedtooccur.Thus,thesedatastronglyindicatethat

thepneumococcalvaccinealoneis10Ð20%effectiveinthe

preventionofpneumonia.Whenalsoincludingtheinßuenza
seasonintheanalysis,thepreventiveeffectagainstpneumo-
niaincreasedfrom9%(95%CI0Ð18)inthegroupreceiving

pneumococcalvaccinationaloneto29%(95%CI25Ð35)in

thosereceivingbothvaccines(table3).Thus,thetwovaccines
wereclearlyadditiveinthepreventionofpneumonia,which
corroboratetheÞndingsofarecentretrospectivecohortstudy

[11].Thesurprisingtendencythatthosewhoreceivedpneu-

mococcalvaccinealonehadalowerrateofhospitalisationfor
inßuenza(OR0.70,95%CI0.49Ð1.03),mayhavebeendueto
thatthisend-pointalsoincludedinßuenzacomplicatedby

pneumonia.Thepatientswhorequiredhospitaltreatmentforinßuenza
orpneumoniadespitehavingreceivedbothvaccineshada
signiÞcantlyshortermeanlengthofstaythanthosewhowere

notvaccinated.Thisshorterlengthofhospitalstaycould
indicatethatthevaccinatedpatientshadobtainedapartial
immunityresultinginalessseveredisease.SigniÞcantlylower

in-hospitalmortalitywasalsodemonstratedforpneumoniain

thosewhohadreceivedbothvaccines,comparedwiththe
unvaccinatedcohort(table4).
Duringtheinßuenzaseason,thereweresigniÞcantlyfewer
hospitaladmissionsforallend-pointdiagnosesinthecohort

vaccinatedwithbothinßuenzaandpneumococcalvaccine
comparedwiththeunvaccinatedone,withareductionof37%
forinßuenza,36%forpneumoniaand72%forIPD(table6).

Theincidencesoftheinvestigateddiagnosesweregenerally

lowerduringthenoninßuenzaseason,andasigniÞcantlower
hospitalisationrateinthevaccinatedgroupwasfoundonly
forpneumonia.
Comparedwiththeunvaccinatedcohort,thereductionof
hospitaladmissionsforIPDvariedfrom53%(95%CI18Ð73)
inthevaccinatedcohort(receivingoneorbothvaccines;

table2)to73%(95%CI-14Ð94)forthosewhoreceived

pneumococcalvaccinealone(table3).Forthegroupwho
weregivenbothvaccines,thereductionwas44%(95%CI
-5Ð70),overall,and72%(95%CI45Ð86)duringtheinßuenza

season.IncontrasttotheÞrststudyyear[23],therewasno

differenceduringthenoninßuenzaseasonbetweenthosewho
hadreceivedpneumococcalvaccinationandthenonvacci-
natedcohortconcerningtheriskforIPD.Thelattermayhave

beenduetochance,sincetheincidenceofIPDduringthat

timeofyearwasverylowandtherewereonlysevencases
amongthosewhohadreceivedbothvaccinesand10casesin
theunvaccinatedcohort.TheimpactonIPDseeninthis

studycorrespondstoÞndingsfromapneumococcaland
inßuenzavaccinationprogrammeforat-riskindigenous
adultsinfarNorthQueensland,Australia[27].Despitea

suboptimalvaccinecoverage,therewasa75%reductionof

theincidenceofIPD,from111to28casesper100,000per
year,duringthe5-yrprogramme.
Animportantquestioninthisstudywaswhetherthe
vaccinatedandunvaccinatedcohortswerecomparable.To

excludetheprobabilitythatthevaccinatedcohortwasata
lowerriskthantheunvaccinatedone,arandomised,multi-
variantstudyamong
y10,000oftheparticipantsinthe
vaccinationstudywasperformed[24].Itwasfoundthatthe

recipientsoftheinßuenzaorpneumococcalvaccinewere
olderandmoreoftenlivinginnursinghomesandinstitutions,
thanthosewhodidnotreceivethevaccination.Inaddition,

personsinthevaccinatedcohorthadsigniÞcantlymore
chroniclungandheartconditions,thanthosewhowerenot
vaccinated,anobservationthatalsohasbeendescribed

elsewhere[25,28].
ThesedataindicatethattheÞndingsmayactuallyunder-
estimate,ratherthanoverestimate,thebeneÞcialeffectof
inßuenzaandpneumococcalvaccination.Inarecentstudyby
NICHOL
etal.
[29],inßuenzavaccinationofelderlypatients
wasassociatedwithareductionintheriskofhospitalisation
forcardiacdisease.IncontrasttotheseÞndings,thepresent
authorsfoundtheriskofhospitalisationduetocardiacfailure

tobethesameinthevaccinatedandtheunvaccinatedcohort

(datanotshown).However,sincechronicheartdiseaseswere
probablymorefrequentintheunvaccinatedthaninthe
vaccinatedcohort[24],thepossibilitythatvaccinationhad

someimpactontheriskofhospitalisationforcardiacdisease
cannotberuledoutinthisstudypopulation.
Theaccuracyofusingmedicalrecorddischargedatacoded
bytheICDforvaccinationefÞcacystudiescanbequestioned.
ArecentstudyshowedthatwhileasingleICDcodehadalow

sensitivity,butacceptablespeciÞcity,theuseoftheÞrstÞve

listedcodes(notonlytheÞrst)andgroupsofcodescould
increasethesensitivitywithoutasubstantialchangein
speciÞcity,positiveornegativepredictivevalues[30].
Toconclude,theseÞndingsconÞrmthatvaccinationof
elderlyindividualswithinßuenzaandpneumococcalvaccines

iseffectiveinpreventinghospitalisationandmortalitycaused
byinßuenza,pneumoniaandinvasivepneumococcaldisease.
Althoughtheinßuenzaandpneumococcalvaccinesseemto

beeffectivewhenusedseparately,theresultsofthepresent
studyalsoindicateanadditivebeneÞtofimmunisingelderly
personswithbothvaccines.
References1.NicholKL.TheadditivebeneÞtofinßuenzaandpneumo-
coccalvaccinationsduringinßuenzaseasonsamongelderly
personswithchroniclungdisease
.Vaccine
1999;17:S91Ð
S93.2.CentersforDiseaseControlandPrevention.Inßuenzaand
pneumococcalvaccinationlevelsamongadultsaged
w65years,UnitedStates,1997
.MMWR
1998;47:797Ð802.
3.GovaertME,ThijsCTMCN,MasurelN,SprengerMJW,
DinantGJ,KnottnerusJA.TheefÞcacyofinßuenza
vaccinationinelderlyindividuals
.JAMA
1994;272:1661Ð
1665.4.FedsonDS,HirotaY,ShinHK,
etal.
Inßuenzavaccination
in22developedcountries:anupdateto1995
.Vaccine
1997;15:1506Ð1511.
5.CentersforDiseaseControlandPrevention.Preventionand
controlofinßuenza:RecommendationsoftheAdvisory
CommitteeonImmunizationPractices
.MMWR
1997;46:1Ð
25.6.AmericanCollegeofPhysicians.GuideforAdultImmuniza-
tion.3rdEdn.Philadelphia,AmericanCollegeofPhysicians,
1994.7.SimberkoffMS,CrossAP,Al-IbrahimM,
etal.
EfÞcacyof
pneumococcalvaccineinhigh-riskpatients
.NEnglJMed
1986;315:1318Ð1327.
8.O
¬rtqvistA
û,HedlundJ,BurmanL-A
û,etal.
Randomisedtrial
of23-valentpneumococcalcapsularpolysaccharidevaccine
inpreventionofpneumoniainmiddle-agedandelderly
people.Lancet
1998;351:399Ð403.
9.KoivulaI,StenM,LeinonenM,Ma
¬kela
¬PH.Clinical
efÞcacyofpneumococcalvaccineintheelderly:arandom-
ized,single-blind,population-basedtrial
.AmJMed
1997;103:281Ð290.
10.GaillatJ,ZmirouD,MallaretMR,
etal.
Clinicaltrialof
pneumococcalvaccineamonginstitutionalisedelderly[Essai
367INFLUENZAANDPNEUMOCOCCALVACCINES
 cliniqueduvaccinanti-pneumococciquechezdespersonnes]
.RevEpide
«miolSante
«Publique
1985;33:437Ð444.
11.NicolKL,BakenL,WuorenmaJ,NelsonA.Thehealthand
economicbeneÞtsassociatedwithpneumococcalvaccination

ofelderlypersonswithchroniclungdisease
.ArchInternMed
1999;159:2437Ð2442.
12.ShapiroED,BergAT,AustrianR,
etal.
Theprotective
efÞcacyofpolyvalentpneumococcalpolysaccharidevaccine
.NEnglJMed
1991;325:1453Ð1460.
13.FarrBM,JohnstonBL,CobbDK,
etal.
Preventingpneumococcalbacteremiainpatientsatrisk.Resultsofa
matchedcase-controlstudy
.ArchInternMed
1995;155:
2336Ð2340.
14.SimsRV,SteinmannWC,McConvilleJH,KingLR,
ZwickWC,SchwartzJS.Theclinicaleffectivenessof

pneumococcalvaccineintheelderly
.AnnInternMed
1988;108:653Ð657.
15.ButlerJC,BreimanRF,CampbellJF,LipmanHB,
BroomeCV,FacklamRR.Pneumococcalpolysaccharide

vaccineefÞcacy.Anevaluationofcurrentrecommendations
.JAMA1993;270:1826Ð1831.
16.BarkerWH,MulloolyJP.Pneumoniaandinßuenzadeaths
duringepidemics:implicationsforprevention
.ArchIntern
Med1982;142:85Ð89.
17.FosterDA,TalsmaA,Furumoto-DawsonA,
etal.
Inßuenzavaccineeffectivenessinpreventinghospitalizationforpneu-

moniaintheelderly
.AmJEpidemiol
1992;136:296Ð307.
18.FedsonDS,WajdaA,NicolP,HammondGW,KaiserDL,
RoosLL.Clinicaleffectivenessofinßuenzavaccinationin
Manitoba.JAMA
1993;270:1956Ð1961.
19.MulloolyJP,BennettMD,HornbrookMC,
etal.
Inßuenzavaccinationprogramsforelderlypersons:cost-effectiveness

inahealthmaintenanceorganization
.AnnInternMed
1994;121:947Ð952.
20.NicholKL,MargolisKL,WuorenmaJ,vonSternbergT.
TheefÞcacyandcosteffectivenessofvaccinationagainst

inßuenzaamongelderlypersonslivinginthecommunity
.NEnglJMed
1994;331:778Ð784.
21.AhmedAH,NicholsonKG,Nguyen-vanTamJS,Pearson
JCG.Effectivenessofinßuenzavaccineinreducinghospital

admissionsduringthe1989Ð90epidemic
.EpidemiolInfect
1997;118:27Ð33.
22.ChristensonB,LundberghP,HedlundJ,O
¬rtqvistA
û.Effects
ofalarge-scaleinterventionwithinßuenzaand23-valent

pneumococcalvaccinesinadults65yearsandolder:a

prospectivestudy
.Lancet
2001;357:1008Ð1011.
23.HedlundJ,ChristensonB,LundberghP,O
¬rtqvistA
û.Effects
ofalarge-scaleinterventionwithinßuenzaand23-valent
pneumococcalvaccinesinelderlypeople:Aone-yearfollow-
up.Vaccine
2003;21:3906Ð3911.
24.ChristensonB,LundberghP.Comparisonbetweencohorts
vaccinatedandunvaccinatedagainstinßuenzaandpneumo-

coccalinfection
.EpidemiolInfect
2002;129:515Ð524.
25.NicholKL,WuorenmaJ,vonSternbergT.BeneÞtsof
inßuenzavaccinationforlow-,intermediate-,andhigh-risk

seniorcitizens
.ArchInternMed
1998;158:1769Ð1776.
26.GrossPA,HermogenesAW,SacksHS,LauJ,Lewandowski
RA.TheefÞcacyofinßuenzavaccineinelderlypersons.A

meta-analysisandreviewoftheliterature
.AnnInternMed
1995;123:518Ð527.
27.HannaJN,YoungDM,BrookesDL,DostieGB,
MurphyDM.Theinitialcoverageandimpactofthe

pneumococcalandinßuenzavaccinationprogramforat-

riskindigenousadultsinFarNorthQueensland
.AustNZ
JPublicHealth
2001;25:543Ð546.
28.GillickMR,DitzonB.Inßuenzavaccination:arewedoing
betterthanwethink?
ArchInternMed
1991;151:1742Ð1744.
29.NicholKL,NordinJ,MulloolyJ,LaskR,FillbrandtK,
IwaneM.Inßuenzavaccinationandreductioninhospital-

izationsforcardiacdiseaseandstrokeamongtheelderly
.NEnglJMed
2003;348:1322Ð1332.
30.GuevaraRE,ButlerJC,MarstonBJ,PlouffeJF,FileTM,
BreimanRF.AccuracyofICD-9-CMcodesindetecting

community-acquiredpneumococcalpneumoniaforincidence

andvaccineefÞcacystudies
.AmJEpidemiol
1999;149:282Ð
289.368B.CHRISTENSONETAL.
